(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Overlooked infertility care should be part of national health services, says WHO - 2The Best Competitors of the 21st Hundred years
- 3Understanding Preschool Projects: Cultivating Abilities and Advancement
- 4Coffee Prices Finish Higher on Brazil Cop Concerns
- 5Scaling New Levels: Rock Climbing Spots On the planet
- Sea level doesn’t rise at the same rate everywhere – we mapped where Antarctica’s ice melt would have the biggest impact
- IDF strikes Shiraz petrochemical site, releases footage of attacks on Iranian air defenses
- Best Disney Palace: Which One Catches Your Creative mind?
- Hostile to Maturing Skincare Items to Rejuvenate Your Skin
- The top astronomical discoveries of 2025
- UK clothing inflation climbs as Middle East turmoil threatens wider price rises
- Starbucks' new 'Bearista' cup is causing a stir — and is being listed on eBay for $600
- Relive NASA's historic Artemis 2 launch to the moon in these stunning photos
- More parents refusing this shot that prevents serious bleeding at birth
